Khan Tengri Biopharma

A full-cycle biopharmaceutical complex with deep localization of pharmaceutical production.

Import of Technologies
Cooperation with international partners and localization

R&D Development
Development of an in-house research base and expert training

International GMP/GLP Standards
Production at world-class quality

Mission and Vision

«From scientific idea to finished medicine — in one country»

Our goal is to achieve a technological breakthrough in the national pharmaceutical industry by establishing in Kazakhstan a modern, export-oriented production of world-class biotechnological products.

We believe that high-quality and affordable medicines should be produced where patients need them most.

Our mission is to ensure Kazakhstan’s pharmaceutical security and to become a regional biopharmaceutical hub.

Strength in partnership

Khan Tengri Biopharma is a strategic alliance between the investment holding "Khan Tengri Capital LLP" and the leader in innovative technologies, the R-Pharm Group of companies.

An international pharmaceutical company — a leader in innovative technologies.
It is engaged in research, development, and manufacturing of pharmaceuticals, laboratory equipment, and medical devices. More than 9 high-tech plants and 6,500+ employees worldwide. Develops monoclonal antibodies and conducts clinical trials in 19 countries; R&D centers in Russia, the USA, India, and China.
An investment holding company that carries out strategic management of projects in the key sectors of Kazakhstan’s economy. Key areas — medicine, pharmaceutical production and biotechnology; research programs and the development of new products; medical equipment and healthcare etc.
Development and localization of production, investments, innovative technologies, and industrial and logistics infrastructure.

Full Cycle: From Cell to Patient

We are creating a production ecosystem unique to the region, covering all stages of modern drug development.

R&D and Development

Research and development of new biotechnological products, monoclonal antibodies, and innovative therapeutic solutions.

Cell Cultivation

Cultivation of cell cultures in bioreactors using advanced technologies for the production of biological substances.

Fermentation and Purification

Fermentation processes and multi-stage purification to obtain high-quality active pharmaceutical ingredients (APIs).

Formulation and Filling

Production of finished dosage forms and filling of sterile vials and syringes in Class A cleanroom conditions.

Quality Control (GMP/GLP)

Multi-level quality control at all stages of production in compliance with international GMP and GLP standards.

Packaging and Distribution

Automated packaging and organization of finished product supply with strict temperature control.

Development of the Pharmaceutical Industry

Address of the President of the Republic of Kazakhstan

9/2021

“It is necessary to intensify cooperation with global pharmaceutical corporations. It is important to attract investors, ensure the transfer of technologies and advanced developments. The volume and range of off-take contracts with domestic manufacturers should be expanded.
The share of domestically produced medicines and medical devices must be increased from the current 17% to 50%.”
Expanded Government Meeting

12/2022

«It is necessary to fundamentally revise the medical equipment procurement system. Regional authorities systematically inflate estimates and equipment prices. Enormous funds are spent on maintenance services. Therefore, I instruct the Government to switch to centralized procurement of medical equipment based on «SK-Pharmacy».»
Decree of the President of the Republic of Kazakhstan «On Measures to Improve the Effectiveness of Investment Attraction to the National Economy»

12/2023
- The powers of the Investment Promotion Council (Investment Headquarters) have been defined.
- Personal responsibility has been established for:
1. the Chairperson and members of the Investment Headquarters — for improving the investment climate and ensuring the timely implementation of investment projects, with a report submitted to the President of the Republic of Kazakhstan at least once per quarter;
2. heads of central and local government bodies, as well as entities of the quasi-public sector — for failure or improper execution of decisions of the Investment Headquarters.

Stages of Implementation and Development of the Biopharmaceutical Complex

From construction and production launch — to a full-cycle operation and export of finished products

Construction and Commissioning of Infrastructure

2026-2027

Execution of construction and installation works, manufacturing and delivery of technological equipment, commissioning activities, and preparation of production infrastructure for operation.

Validation and Personnel Training

2027-2028

Validation of technological processes and equipment, training and certification of production and engineering staff, registration and certification of the production site in accordance with regulatory requirements.

Production Launch

2028 год

Launch of industrial production and release of the first commercial batch.

Deepening Localization of Key Products

2029

Increase in localization level across the entire product portfolio, full transfer and mastery of complex biotechnological processes for key products.

Formation of a Scientific and Industrial Ecosystem

2031

Establishment of a scientific and technological base for pharmaceutical R&D, full localization of the biotechnological production cycle, and development of a sustainable local supply chain.

Production and Export

2032

Establishment of a full-cycle production in Kazakhstan, reaching design capacity and launch of export activities.

Production Facilities

Production Building No. 1

Solid dosage forms: